市場調査レポート

商品コード

1461635

アプタマーの世界市場規模、シェア、成長分析、タイプ別、用途別-産業予測、2024～2031年

Global Aptamers Market Size, Share, Growth Analysis, By Type(Nucleic Acid and Peptide), By Application(Diagnostics, Therapeutics) - Industry Forecast 2024-2031

出版日: 2024年04月02日 | 発行: SkyQuest

| ページ情報: 英文 219 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 830,828円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 971,912円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,112,996円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
目次

概要

サンプル依頼リストに入れる

アプタマーの世界市場規模は2022年に12億米ドルと評価され、予測期間中（2024～2031年）のCAGRは19.2%で、2023年の14億3,000万米ドルから2031年には58億3,000万米ドルに成長する展望です。

アプタマーは、生産、精製、標的ドラッグデリバリーにおいて、分子サイズが小さい、免疫原性が低い、費用対効果が高い、抗体と比較して副作用が少ないなどの利点があり、その明確な利点により、調査から大きな関心を集めています。このことがアプタマー開発の技術革新に拍車をかけ、市場を拡大する可能性があります。さまざまな遺伝子変異があるにもかかわらず、感染症に対する現在の治療法は有効性に欠け、先進的な解決策が必要となっています。SELEX技術に基づく診断キットは、高親和性中和剤の生産に有望であり、市場拡大の原動力となる可能性が高いです。第2世代のDNAアプタマーベースのアプタマーのようなアプタマーベースの診断キットは、EPIC調査で利用されたSoma LogicのSomaScan Assayに代表されるように、コスト効率が高く化学合成されたソリューションを提供し、より深い疾患理解を可能にし、Cancer Research UKが予測するがん診断需要の高まりに対応する市場成長を促進します。アプタマーベースの診断ソリューションは、その小さなサイズ、高い特異性、選択性、有効性により、細胞レベルの疾患診断に好まれており、2040年までに予想されるがん診断の増加に対応しています。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料の分析
イノベーションマトリクス
パイプライン製品の分析
マクロ経済指標
主要投資の分析
主要成功要因
競合の程度

市場力学と展望

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制情勢
ポーターの分析
将来の混乱についての特別な考察

アプタマーの世界市場：タイプ別

市場概要
核酸とペプチド

アプタマーの世界市場：用途別

市場概要
診断
治療
研究開発
その他

アプタマーの世界市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2021年）
主要市場企業が採用した戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア（2021年）

主要企業プロファイル

NeoVentures Biotechnology Inc.（米国）
Base Pair Biotechnologies, Inc.（米国）
Aptagen, LLC（米国）
SomaLogic, Inc.（米国）
Vivonics, Inc.（米国）
Aptamer Sciences, Inc.（米国）
TriLink BioTechnologies, LLC（米国）
AMS Biotechnology Europe Ltd.（英国）
Aptamer Group Ltd.（英国）
NOXXON Pharma AG（ドイツ）
AM Biotechnologies, LLC（米国）
Aptus Biotech S.L.（スペイン）
Aptamer Group（英国）
Ophthotech Corporation（米国）
Vivonics, Inc.（米国）
ATDBio Ltd.（英国）
Base Pair Biotechnologies, Inc.（米国）
Am Biotechnologies, LLC（米国）
Aptamer Sciences, Inc.（米国）
Orla Protein Technologies Ltd.（英国）
Archemix Corp.（米国）
AptaMatrix（米国）

Product Code: SQMIG35E2038

Global Aptamers Market size was valued at USD 1.20 billion in 2022 and is poised to grow from 1.43 USD billion in 2023 to USD 5.83 billion by 2031, at a CAGR of 19.2% during the forecast period (2024-2031).

Aptamers have attracted significant interest from researchers due to their distinct advantages in production, purification, and targeted drug delivery, offering benefits such as small molecular size, low immunogenicity, cost-effectiveness, and reduced side effects compared to antibodies. This has spurred innovation in aptamer development, potentially expanding the market. Despite various genetic variations, current therapies for infections lack effectiveness, prompting the need for advanced solutions. SELEX technology-based diagnostic kits offer promise in producing high-affinity neutralizers, likely driving market expansion. Aptamer-based diagnostic kits, like the second-generation DNA aptamer-based Aptamer, offer cost-effective and chemically synthesized solutions, exemplified by Soma Logic's SomaScan Assay, utilized in the EPIC research, enabling deeper disease understanding and facilitating market growth to meet rising cancer diagnostic demands predicted by Cancer Research UK. With their small size, high specificity, selectivity, and efficacy, aptamer-based diagnostic solutions are preferred in cellular-level disease diagnosis, catering to the anticipated increase in cancer diagnoses by 2040.

Top-down and bottom-up approaches were used to estimate and validate the size of the global aptamers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Aptamers Market Segmental Analysis

Global Aptamers Market is segmented on the basis of type, application and region. By type, the market is segmented into nucleic acid and peptide. By application, market is segmented into diagnostics, therapeutics, research & development, others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Aptamers Market

Aptamers are integral to personalized medicine due to their ability to selectively bind to various target molecules like proteins, peptides, and small molecules. With the rising focus on tailored therapies and precision medicine, there's a heightened need for aptamers owing to their distinct benefits such as exceptional specificity, minimal immunogenicity, and customizable attributes. By facilitating precise molecular recognition, aptamers pave the way for the formulation of individualized treatment approaches, thereby playing a pivotal role in advancing personalized medicine strategies.

Restraints in the Global Aptamers Market

The advancement of the aptamers market faces obstacles due to intellectual property (IP) challenges, wherein patent rights and licensing agreements concerning aptamers and associated technologies may constrain their commercialization potential, particularly for specific applications or targets. The intricate IP landscape surrounding aptamer-based technologies introduces legal uncertainties and potential obstacles for market participants, impeding their growth prospects.

Market Trends of the Global Aptamers Market

The primary technique for aptamer selection, known as SELEX (Systematic Evolution of Ligands by Exponential Enrichment), is increasingly emphasizing optimization and automation to bolster efficiency, cut down expenses, and enhance the quality of aptamers. Innovations in high-throughput screening, microfluidics, and robotics are being harnessed to streamline the aptamer development workflow, thus democratizing and scaling up the process for wider accessibility.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Aptamers Market by Type

Market Overview
Nucleic Acid and Peptide

Global Aptamers Market by Application

Market Overview
Diagnostics
Therapeutics
Research & Development
Others

Global Aptamers Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

NeoVentures Biotechnology Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Base Pair Biotechnologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptagen, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SomaLogic, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vivonics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TriLink BioTechnologies, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AMS Biotechnology Europe Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Group Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NOXXON Pharma AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AM Biotechnologies, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptus Biotech S.L. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Group (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ophthotech Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vivonics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ATDBio Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Base Pair Biotechnologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Am Biotechnologies, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptamer Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orla Protein Technologies Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Archemix Corp. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AptaMatrix (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments